Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alicaforsen - Atlantic Healthcare

Drug Profile

Alicaforsen - Atlantic Healthcare

Alternative Names: Alicaforsen enema; Alicaforsen sodium; AP 1007; AP 1431; AP 1450; AP 1451; Camligo; ISIS 2302

Latest Information Update: 05 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Atlantic Healthcare
  • Class Anti-inflammatories; Antipsoriatics; Antisense oligonucleotides; Thionucleotides
  • Mechanism of Action Immunosuppressants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pouchitis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Pouchitis; Ulcerative colitis

Highest Development Phases

  • Phase III Crohn's disease
  • Phase II Ulcerative colitis
  • No development reported Pouchitis
  • Discontinued Asthma; Inflammation; Psoriasis; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 15 Aug 2022 Ionis Pharmaceuticals completes phase III clinical trials in Crohn's disease in Belgium, Czech Republic, Germany, Italy, Poland, Spain (IV) (NCT00048295)
  • 02 Feb 2022 Atlantic Healthcare has patent protection for Alicaforsen in USA for the treatment of inflammatory bowel disease
  • 03 Oct 2021 Updated adverse events, efficacy and pharmacokinetics data from a phase III trial in Pouchitis presents at the 29th United European Gastroenterology Week (UEGW-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top